BioCryst

CIK 0000882796 · BCRX Nasdaq

SIC
2836 · Biological Products, Except Diagnostic
Type
Operating
Status
Public
Filer
Large accelerated filer
Incorporated
Delaware
FY End
Dec 31

Business Summary

BioCryst Pharmaceuticals is a global rare disease biotechnology company focused on developing and commercializing small molecule and injectable protein therapeutics, with its lead commercial product ORLADEYO (berotralstat) — the first and only oral once-daily prophylactic therapy for hereditary angioedema (HAE). The company has built a commercial infrastructure around ORLADEYO in the U.S. and select global markets, and in January 2026 completed the acquisition of Astria Therapeutics to add navenibart, a Phase 3 injectable monoclonal antibody for HAE, expanding its rare disease pipeline. BioCryst's strategy centers on leveraging its established commercial platform and structure-guided drug design capabilities to advance both internally discovered and externally acquired rare disease assets.

Products & Services

  • ORLADEYO (berotralstat) — Approved oral once-daily HAE prophylaxis for adults/pediatrics ≥12 (U.S., multiple global markets); FDA-approved December 2025 in oral pellet form for pediatric patients aged 2 to <12. Estimated peak global revenue potential of...
Get a free account in seconds to read the full business overview. Create free account

AI-generated summary of Item 1 (Business) from the 10-K filed Feb 26, 2026 — View filing on SEC.gov. May contain errors — refer to the filing for authoritative information.

Across SEC filings

Institutional holders · 13F

Q3 2026
333 managers reported a position for Q3 2026 +12 vs Q2 2026
Largest Q3 2026 Form 13F holders of BioCryst by reported value
Largest holders Reported value
BlackRock Inc $202.7M
DEERFIELD MANAGEMENT COMPANY L P SERIES C $129.0M
STATE STREET CORPORATION $102.4M
VANGUARD CAPITAL MANAGEMENT LLC $93.9M
TCG Crossover Management LLC $91.8M

Annual results · 10-K

Fiscal 2025
Revenue
$874.8M
Net income
$263.9M

As reported in the fiscal 2025 annual report.

Funds & ETFs · N-PORT

Loading fund holders…

Securities

Securities issued by this company
CUSIP Security Type
09058V103 BCRX BIOCRYST PHARMACEUTICALS INC Common stock

Insider trades · Form 4

-$4.07M net open-market insider transactions, last 12 months 0 filings with purchases ($0), 7 filings with sales ($4.07M)

Latest filings

5%+ holders · 13D/G

4 filers
Schedule 13D and 13G filers reporting a stake of 5% or more
Filer % of class Filed
STATE STREET CORPORATION 13G 4.8% 2026-11-10
VANGUARD CAPITAL MANAGEMENT LLC 13G 5.2% 2026-04-29
Deerfield Mgmt L P 13G 6.8% 2026-02-12
BlackRock Inc 13G 8.4% 2025-04-17

Latest Schedule 13D or 13G from each filer; stakes a filer has reported closed are left out.

Federal lobbying · LD-2

$10.0K reported spend, four quarters through Q2 2019

Latest SEC filings

All filings →
Latest SEC filings by BioCryst
Form Description Filed
SCHEDULE 13G/A SCHEDULE 13G/A 2026-11-16
SCHEDULE 13G SCHEDULE 13G 2026-11-10
10-Q Quarterly Report 2026-11-04
8-K Current Report 2026-11-04
4 PRIMARY DOCUMENT 2026-09-02
4 PRIMARY DOCUMENT 2026-09-02
4 PRIMARY DOCUMENT 2026-09-02
4 PRIMARY DOCUMENT 2026-09-02
4 PRIMARY DOCUMENT 2026-09-02
SCHEDULE 13G/A SCHEDULE 13G/A 2026-08-14
Loading ownership data...
Loading insider trading data...
Loading financials...

Quality is a Plus feature

See why the score is what it is — the score history and the full test-by-test breakdown behind the composite.

Valuation is a Premium feature

What this company is worth versus its price — fair value at today's bond rate, margin of safety, and the Graham Number against the institutional consensus price.

Loading SEC filings...
Loading sponsor profile...